CHOP

CHOP is the acronym for a chemotherapy regimen used in the treatment of non-Hodgkin lymphoma. CHOP consists of: Cyclophosphamide, an alkylating agent which damages DNA by binding to it and causing the formation of cross-links (also called doxorubicin or adriamycin), an intercalating agent which damages DNA by inserting itself between DNA bases (vincristine), which prevents cells from duplicating by binding to the protein tubulin or , which are corticosteroids. Sometimes the chimeric anti-CD20 monoclonal antibody, rituximab, is added to this treatment regimen to form the R-CHOP regimen. Dosing regimen R-Maxi-CHOP is used in mantle cell lymphoma and is given in 21-day intervals, alternating with R-HDAC (rituximab + high-dose cytarabine).